Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: A systematic review

Tavakolpour, Soheil; Mahmoudi, Hamidreza; Balighi, Kamran; Abedini, Robabeh; Daneshpazhooh, Maryam

doi:10.1016/j.intimp.2017.11.005

Cited by 68 publications

(79 citation statements)

References 110 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…13 Over the past 15 years, more than 1,000 pemphigus patients treated with rituximab (monoclonal antibody against the CD20 molecule on B lymphocytes) have been reported in the literature. 14 Rituximab has first been used to treat severe forms (recalcitrant or relapsing types) and later as first-line treatment reaching complete remissions in 80-90% of patients. [15][16][17][18] Recently, a randomized controlled trial with newly diagnosed patients with PV and PF showed that 89% of patients assigned to the rituximab group achieved complete remission off therapy versus 34% of patients assigned to treatment with prednisone alone.…”

Section: Introductionmentioning

confidence: 99%

Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV)

Joly

Hórvath

Patsatsi

et al. 2020

Acad Dermatol Venereol

190

302

View full text Add to dashboard Cite

Background Pemphigus encompasses a group of life‐threatening autoimmune bullous diseases characterized by blisters and erosions of the mucous membranes and skin. Before the era of immunosuppressive treatment, pemphigus was almost always fatal. Due to its rarity, only few randomized controlled therapeutic trials are available. Recently, rituximab has been approved as first‐line treatment for moderate and severe pemphigus vulgaris in Europe and the United States. Objectives The Autoimmune blistering diseases Task Force of the European Academy of Dermatology and Venereology (EADV) has initiated a throughout update of the guideline for the management of patients with pemphigus. Results The guidelines for the management of pemphigus were updated, and the degree of consent among all task force members was included. The final version of the guideline was consented by the European Dermatology Forum (EDF) and several patient organizations.

show abstract

Section: Introductionmentioning

confidence: 99%

Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV)

Joly

Hórvath

Patsatsi

et al. 2020

Acad Dermatol Venereol

190

302

View full text Add to dashboard Cite

show abstract

“…Unfortunately, because of the low global prevalence of pemphigus, several high potent treatments have remained unmet. Over the last decade, increasing evidences show the high efficacy of rituximab (an anti-CD20 monoclonal antibody) in the induction of long-lasting remission in those patients who do not respond to conventional treatments (Tavakolpour, Mahmoudi, Balighi, Abedini, & Daneshpazhooh, 2018). There is also some emerging evidence to support that it could be administrated as the first-line treatment for pemphigus (Joly et al, 2017).…”

mentioning

confidence: 99%

Tofacitinib as the potent treatment for refractory pemphigus: A possible alternative treatment for pemphigus

Tavakolpour

2018

Dermatologic Therapy

Self Cite

View full text Add to dashboard Cite

Pemphigus is a rare, but life-threatening autoimmune disease with a high rate of morbidity and mortality, if left untreated. After the development of corticosteroid therapy in the 1950s, the death rate for pemphigus has significantly decreased. However, finding more potent therapeutic options for refractory patients has remained a controversial topic. In the recent years, rituximab has increasingly been used for the treatment of refractory pemphigus, but some patients do not well-respond. In addition, there is a paucity of evidence to support the risk of diseases exacerbation after rituximab therapy. In this study, as a JAK1 and JAK3 inhibitor, tofacitinib has been proposed for the treatment of refractory pemphigus patients.

show abstract

“…During the recent decade, rituximab has been presented as an alternative treatment in pemphigus patients and also has been suggested as potential first-line therapy in moderate to severe patients (Joly et al, 2017;Tavakolpour, Mahmoudi, Balighi, Abedini, & Daneshpazhooh, 2018). In addition to relatively long-lasting remission, it can accelerate safe steroid tapering.…”

mentioning

confidence: 99%

Anti-desmoglein-1 levels as predictor of prednisolone tapering in pemphigus vulgaris patients treated with rituximab

Balighi

Sakhi

Daneshpazhooh

et al. 2018

Dermatologic Therapy

Self Cite

View full text Add to dashboard Cite

Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: A systematic review

Cited by 68 publications

References 110 publications

Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV)

Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV)

Tofacitinib as the potent treatment for refractory pemphigus: A possible alternative treatment for pemphigus

Anti-desmoglein-1 levels as predictor of prednisolone tapering in pemphigus vulgaris patients treated with rituximab

Contact Info

Product

Resources

About